OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
license
Q BioMed Inc. finalizes license agreement with OMRF, RGCB
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
New OMRF vice president focuses on bringing discoveries to the world
Technology Ventures works to pair scientists with industry partners.
